Can a Postbiotic Pill Protect Our Bodies from Ingested Microplastics?

SARASOTA, Fla. — September 30, 2026 — Micro- and nanoplastics have become the inescapable phantoms of the modern environment. They drift in the air we breathe, swirl in the water we drink, and embed themselves in the food we consume. In recent years, scientists have detected these synthetic fragments in human blood, lung tissue, and even placentas. While consumers can attempt to mitigate exposure by avoiding plastic water bottles and synthetic cutting boards, the sheer ubiquity of plastic pollution makes complete avoidance mathematically impossible.

Now, a new frontier in biotechnology is attempting to address the plastic epidemic not by cleaning the oceans, but by fortifying the human gut.

New peer-reviewed research published in Frontiers in Microbiology details the first human in-vivo proof-of-concept evidence of an administered technology intentionally designed to physically capture microplastics within the body. The study centers on Qi601, a proprietary, non-living postbiotic developed by Florida-based Quorum Innovations. The compound is designed to bind micro- and nanoplastics within the gastrointestinal tract before they can interact with, or be absorbed by, intestinal cells.

The Science of Sequestration

The premise behind Qi601 relies on the physical properties of a specific strain of heat-inactivated bacteria, Limosilactobacillus fermentum LfQi6. Unlike traditional live probiotics, Qi601 is a postbiotic—a preparation of inanimate microorganisms and their components that confers a health benefit. In this case, the postbiotic acts as a high-surface-area biofilm matrix that self-aggregates and traps foreign particles.

To test this in a human setting, researchers conducted a unique exploratory trial utilizing chewing gum, a common and often overlooked source of microplastic ingestion. Researchers directly observed microplastic particles released from the gum physically associating with Qi601 agglomerates in human saliva. The results were striking: in the saliva samples containing both the gum and Qi601, the presence of free-floating microplastic particles was approximately 91 percent lower than in the control samples containing only the gum.

"For the first time, a published human proof-of-concept study shows a technology intentionally designed to capture microplastics physically associating with those particles in a human setting," said Eva A. Berkes, MD, co-founder, Chief Science Officer of Quorum Innovations, and lead author of the study. "This opens an entirely new approach to unavoidable plastic exposure."

The researchers did not stop at the mouth. Follow-on laboratory studies simulated the harsh environments of oral, stomach, and intestinal digestion. In these in-vitro models, Qi601 retained a 92 percent depletion rate of nanoplastics. Furthermore, when introduced to human colon cell models—specifically Caco-2 intestinal epithelial monolayers, the gold standard for testing gut absorption—Qi601 captured and prevented 98 percent of nanoplastics from entering the human cells.

From Battlefield Defense to Gut Protection

The development of Qi601 is rooted in research originally aimed at protecting military personnel. Quorum Innovations, founded by physician-scientists Dr. Eva Berkes and Dr. Nicholas Monsul, has a deep history in biotherapeutic and barrier-defense technologies. The company previously received two Direct-to-Phase II research awards from the Defense Advanced Research Projects Agency (DARPA).

These military grants were focused on developing barrier-defense technologies for warfighters, aiming to protect against chemical and biological threats using the natural properties of microbial biofilms to deflect or trap foreign contaminants. By pivoting this defense mechanism toward synthetic polymers, Quorum Innovations has adapted battlefield technology into a potential consumer health application. The company currently holds more than 55 U.S. and international patents surrounding their microbiome and biofilm innovations.

"Qi601 represents a fundamentally different approach: barrier protection through physical sequestration," said Nicholas T. Monsul, MD, co-founder, CEO, and study co-author. "You take Qi601 by mouth as a supplement. The goal is to capture these particles in the gastrointestinal tract, reduce their interaction with intestinal cells and facilitate their natural elimination."

Navigating Regulatory Pathways and Commercialization

As Quorum Innovations moves toward commercializing this technology, understanding the regulatory landscape is critical. The underlying ingredient of Qi601, Limosilactobacillus fermentum LfQi6, has received a Generally Recognized as Safe (GRAS) notice letter from the FDA (GRN 000988).

However, it is vital to distinguish between an ingredient's safety profile and its clinical efficacy. A GRAS designation means the FDA acknowledges the ingredient is safe for consumption in food or dietary supplements. It does not mean the FDA has evaluated or endorsed the compound as a medical treatment or a definitive "cure" for plastic ingestion.

Because Qi601 is positioned to be taken by mouth as a supplement, it will likely enter the booming, yet loosely regulated, dietary supplement market. Under FDA guidelines, supplement manufacturers cannot claim their products diagnose, treat, cure, or prevent any disease. Therefore, marketing a product as a microplastics "detox" will require careful navigation of regulatory claims, focusing on structural and functional benefits—such as supporting gut barrier integrity—rather than disease prevention.

Despite these regulatory hurdles, the commercial appetite for a daily supplement that mitigates plastic exposure is immense. As public awareness of nanoplastic pollution reaches a fever pitch, a scientifically backed postbiotic could disrupt the multi-billion-dollar wellness industry, creating an entirely new category of environmental defense supplements.

Healthy Skepticism: A Preliminary Step or a Panacea?

While the data published in Frontiers in Microbiology is groundbreaking, independent experts caution against viewing Qi601 as an immediate panacea for the plastic crisis. The scientific community is approaching the findings with a blend of intense interest and necessary skepticism.

Independent toxicologists note that while the in-vitro and simulated digestion results are compelling, binding particles in a laboratory flask or a saliva sample is vastly different from clearing them from a dynamic, living human body. The human gastrointestinal tract is a highly complex environment influenced by diet, existing microbiome diversity, and varying transit times.

Furthermore, experts emphasize a critical limitation of any gut-based barrier technology: it cannot address the existing "body burden." Micro- and nanoplastics that have already crossed the intestinal barrier and lodged in human tissues, organs, or the bloodstream are entirely out of reach for an ingested postbiotic. Qi601 is designed as a preventative shield for newly ingested plastics, not a systemic cleanser for historical exposure.

Researchers specializing in environmental health also point out that while preventing cellular uptake in colon models by 98 percent is a phenomenal laboratory achievement, long-term human clinical trials are essential. It remains to be seen whether regular consumption of Qi601 leads to a statistically significant, measurable reduction in the overall plastic load within human tissues over months or years. There are also lingering questions about whether the physical bonds between the postbiotic and the plastics remain stable throughout the entire length of the lower intestine until natural elimination occurs.

Despite these caveats, the publication of this proof-of-concept study marks a pivotal moment in environmental medicine. For years, the medical community has been sounding the alarm on microplastics without offering patients any actionable biological defense. By demonstrating that an administered postbiotic can physically target and sequester synthetic polymers in a human setting, researchers have moved the conversation from passive observation to active intervention.